Provided by Tiger Fintech (Singapore) Pte. Ltd.

Cardiff Oncology, Inc.

2.64
+0.270011.39%
Post-market: 2.640.00000.00%19:44 EDT
Volume:5.88M
Turnover:15.25M
Market Cap:175.63M
PE:-3.03
High:2.79
Open:2.46
Low:2.39
Close:2.37
Loading ...

Craig-Hallum Sticks to Its Buy Rating for Cardiff Oncology (CRDF)

TIPRANKS
·
09 May

Cardiff Oncology Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
09 May

Cardiff Oncology Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
09 May

Cardiff Oncology Q1 EPS $(0.20) Misses $(0.19) Estimate, Sales $109.00K Beat $96.43K Estimate

Benzinga
·
09 May

Cardiff Oncology announces second patent for onvansertib combination

TIPRANKS
·
24 Apr

Cardiff Oncology Announces a Second Patent for the Treatment of mCRC for Bev-Naïve Patients

GlobeNewswire
·
24 Apr

Cardiff Wraps Up Enrollment in Phase 2 Trial of Prospective Colorectal Cancer Treatment

MT Newswires Live
·
16 Apr

BRIEF-Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
16 Apr

Cardiff Oncology Announces Completion of Enrollment in Phase 2 CRDF-004 Trial Evaluating Onvansertib for the Treatment of First-line RAS-mutated Metastatic Colorectal Cancer

GlobeNewswire
·
16 Apr

Cardiff Oncology initiated with a Buy at Lucid Capital

TIPRANKS
·
03 Apr

Cardiff Oncology Full Year 2024 Earnings: Beats Expectations

Simply Wall St.
·
01 Mar

Cardiff Oncology Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
28 Feb

Cardiff Oncology price target raised to $17 from $13 at H.C. Wainwright

TIPRANKS
·
28 Feb

Analysts Offer Insights on Healthcare Companies: TransMedics Group (TMDX) and Cardiff Oncology (CRDF)

TIPRANKS
·
28 Feb

Cardiff Oncology Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
28 Feb

William Blair Keeps Their Buy Rating on Cardiff Oncology (CRDF)

TIPRANKS
·
28 Feb

BRIEF-Cardiff Oncology Files For Mixed Shelf Of Up To $400 Million – SEC Filing

Reuters
·
28 Feb

Cardiff Oncology Q4 GAAP EPS $(0.21) Beats $(0.24) Estimate, Sales $151.00K Beat $94.17K Estimate

Benzinga
·
28 Feb

Press Release: Cardiff Oncology Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update

Dow Jones
·
28 Feb

Cardiff Oncology Inc expected to post a loss of 24 cents a share - Earnings Preview

Reuters
·
26 Feb